Clinical trials: Aripiprazole, completed
Bipolar Disorder
Abilify in Bipolar Disorder for 6 Weeks Treatment Effectiveness
To demonstrate the efficacy and safety of co-administration of Abilify(aripiprazole) with Depakote(divalproate) in the acute phase of 6-week treatment of acute mania in patients with bipolar disorder.
- Trial name
- SMART-A (NCT00545142)
- Testing
- Abilify(Aripiprazole), Depakote(Divalproate)
- Where
- South Korea
- Volunteers
- 280 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Body Weight Change, Schizophrenia
Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder
The primary purpose of this study is to compare the affects of aripiprazole and olanzapine on weight change.
- Conditions
- Body Weight Change, Schizophrenia, Schizoaffective Disorder, Psychotic Disorder
- Trial name
- NCT00095524
- Testing
- Aripiprazole
- Where
- 32 sites in United States, Brazil and 1 more
- Volunteers
- 300 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Autism
Post-Marketing Surveillance Study of Aripiprazole in Patients With Autism
The purpose of this study is to evaluate the safety and effectiveness of aripiprazole in patients with autism in the real world clinical setting in Japan.
- Trial name
- NCT03179787
- Testing
- Aripiprazole oral product
- Where
- Japan
- Volunteers
- 528 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Major Depressive Disorder
Canadian Biomarker Integration Network for Depression Study
This study is a pilot to assess feasibility of the protocol in patients and controls across six participating sites. The goal is to identify biological markers (biomarkers)that can be measured at baseline or early in treatment to…
- Trial name
- CAN-BIND-1 (NCT01655706)
- Testing
- escitalopram, aripiprazole
- Where
- 6 sites in Canada
- Volunteers
- 211 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Schizophrenia
Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia
This study will evaluate the effectiveness of galantamine and CDP-choline in improving symptoms associated with schizophrenia.
- Trial name
- STAR-1 (NCT00509067)
- Testing
- Galantamine, CDP-choline, risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Georgetown University
Schizophrenia
Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis
This 52 week long study evaluates the effectiveness of aripiprazole versus risperidone in treating people with first-episode schizophrenia.
- Trial name
- NCT00320671
- Testing
- Aripiprazole, Risperidone
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- Northwell Health
Schizophrenia, Psychotic Disorders
Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up
Cognitive enhancement is a primary goal in treating individuals with schizophrenia. Cognitive deficits are already present at the first break of the illness, seem to remain stable during early phases and noticeably influence…
- Trial name
- PAFIP2_nc1Y (NCT02534363)
- Testing
- Aripiprazole, Quetiapine, Ziprasidone
- Where
- Spain
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Chronic Low Back Pain, Negative Affectivity
Treating Negative Affect in Low Back Pain Patients
This study will examine how the use of antidepressant, physical therapy, and combination of both affects pain, function, and depression outcomes in chronic low back pain patients.
- Trial name
- TNA-LBP (NCT04747314)
- Testing
- Antidepressant, Enhanced Fear Avoidance Rehabilitation
- Where
- 3 sites in United States
- Volunteers
- 308 people
- Sponsor
- Ajay Wasan, MD, Msc
Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy
The purpose of this study is to determine whether a reduced dose of aripiprazole is effective in treating patients with major depressive disorder
- Trial name
- NCT00683852
- Testing
- Aripiprazole 5mg, Aripiprazole 2mg
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- Massachusetts General Hospital
Metabolic Syndrome X
Identification and Treatment Response Prediction of Antipsychotic-Related Metabolic Syndrome
The investigators developed an easy identification model to identify metabolic syndrome in patients with schizophrenia or schizoaffective disorder who received treatment of clozapine, olanzapine, or risperidone.
- Trial name
- NCT00956189
- Testing
- amisulpride, aripiprazole
- Where
- 3 sites in Taiwan
- Volunteers
- 132 people
- Sponsor
- National Taiwan University Hospital
Acute Schizophrenia, Schizoaffective Disorder
RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
The objective of this study is to evaluate the efficacy and safety of RP5063 relative to placebo for the treatment of schizophrenia or schizoaffective disorder.
- Trial name
- REFRESH (NCT01490086)
- Testing
- RP5063, aripiprazole
- Where
- 15 sites in United States, India and 3 more
- Volunteers
- 234 people
- Sponsor
- Reviva Pharmaceuticals
Posttraumatic Stress Disorder
Aripiprazole in the Treatment of Post-Traumatic Stress Disorder Symptoms
32 outpatients with a Posttraumatic Stress Disorder were included in a randomized comparative single-blind study to study the efficacy of aripiprazole to treat post-traumatic stress symptoms.
- Trial name
- AripipPTSD (NCT00440713)
- Testing
- Aripiprazole, Interpersonal Therapy
- Volunteers
- 40 people
- Sponsor
- Federal University of São Paulo
Acute Schizophrenia Episode
Pharmacologic Treatment of Acute Episode of Schizophrenia: a Real World Study
This study attempts to observe the effectiveness and safety of aripiprazole in hospitalized patients with acute schizophrenia episode, and to compare the different drug regimens that may be involved in order to clarify the…
- Trial name
- NCT03289026
- Testing
- Aripiprazole
- Where
- 12 sites in China
- Volunteers
- 770 people
- Sponsor
- Peking University
Healthy
A Study to Compare Capillary and Venous Whole Blood and Plasma Concentrations of Five Antipsychotics
The purpose of this study is to compare capillary (the smallest of a body's blood vessels) and venous whole blood and plasma concentrations of 5 antipsychotics after given of a single oral, immediate-release dose to healthy…
- Trial name
- NCT01607762
- Testing
- Aripiprazole, Quetiapine, Olanzapine
- Where
- Belgium
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC